Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(27 sites)
United States
University of California, Davis, Davis, California Kaiser Permanente Medical Center, Sacramento, California Quest Clinical Research, San Francisco, California Denver Health Medical Center, Denver, Colorado Alliance Clinical, Las Vegas, Las Vegas, Nevada Cleveland Clinic, Cleveland, Ohio Prime Clinical Research Inc, Mansfield, Texas University of Utah, Salt Lake City, Utah Belgium
Erasme Hospital, Brussels University Hospital Antwerp (UZA), Edegem University Hospital Center Sart-Tilman, Liège Bulgaria
Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda, Sofia Georgia
Hospital Service LTD, Kutaisi JSC T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi LTD Academician Vakhtang Bochorishvili Clinic, Tbilisi Hungary
Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest Fejer County St. Gyorgy University Teaching Hospital, Székesfehérvár Israel
Soroka University Medical Center, Beersheba HaEmek Medical Center, Haifa Pakistan
Aga Khan University & Hospital, Karachi, Karachi Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City E-Da Hospital, Kaohsiung City National Taiwan University Hospital, Taipei Ukraine
Limited Liability Company "Medical Center Health and Rehabilitation "100 Percent Life", Poltava Public Non-Profit Enterprise "Central City Hospital" of Rivne City Council, Rivne Uzbekistan
Research Institute of Virology of the Republic of Uzbekistan, Tashkent